Профилактика и лечение острой респираторной вирусной инфекции у пациентов с впервые выявленным туберкулезом легких

Abstract

A tuberculosis patient with bacterial discharge requires a long-term inpatient treatment. During this time he/she may have several episodes of acute respiratory viral infections (ARVI). It is of scientific and practical interest to develop approaches to the treatment and prevention of ARVI in patients with first-time tuberculosis (TB). Objective: To assess the efficacy and safety of the recombinant interferon-based medication Grippferon® with loratadine (nasal ointment) for prevention and treatment of acute respiratory viral infections (ARVI) in patients with first-time tuberculosis. Patients and methods: A comparative, prospective, open study was conducted which included two stages. During the first stage two groups of patients with the first-time tuberculosis were compared: 25 patients in each group. Main group patients received the medication Grippferon® with loratadine for the treatment of ARVI. The second stage included two groups of patients with first-time tuberculosis: 100 patients in each group. Main group patients received the medication Grippferon® with loratadine for the prevention of ARVI. Results and conclusion: Based on our study results, we can conclude that the use of the medication Grippferon® with loratadine in the complex treatment of ARVI improved the therapy efficacy, reduced the severity and duration of the respiratory disease symptoms, while maintaining normal quality of life. We observed that main group patients, who received Grippferon® with loratadine for the ARVI prevention (seven days course), were less likely to develop ARVI, than control group ones (12% vs. 35%; χ2 = 9.19, p = 0.002), and the disease itself was shorter and milder. Keywords: ARVI, treatment, prevention, Grippferon with loratadine, patients with first-time tuberculosis